Cystic Fibrosis Research

Cystic fibrosis (CF) is a common inherited disease that mostly affects the lungs and airways of a sufferer. One of the main pathological characteristics of CF is the failure of airway defence against bacterial infection, leading to frequent chest infection and progressive lung damage.

Cystic Fibrosis Research Products Targets

Products for Cystic Fibrosis Research - Page 6

Cat.No. Product Name Information/Activity
BCC7356 BIBU 1361 dihydrochloride Selective inhibitor of EGFR-kinase
BCC1449 Canertinib dihydrochloride Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM.
BCC7667 CGP 52411 CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC50 of 0.3 μM. CGP52411 blocks the toxic influx of Ca2+ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease.
BCC1306 3,3'-Diindolylmethane 3,3'-Diindolylmethane is a strong, pure androgen receptor (AR) antagonist.
BCN5499 Genistein Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
BCC7300 GW 583340 dihydrochloride 1173023-85-2
BCC7441 HDS 029 881001-19-0
BCC6046 HKI 357 HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.
BCN2173 Gefitinib Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity.
BCC7662 JNJ 28871063 hydrochloride 944342-90-9